Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord InjuryPRNewsWire • 07/18/24
Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple SclerosisPRNewsWire • 06/26/24
Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug DiscoveryPRNewsWire • 05/07/24
Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued ListingPRNewsWire • 04/24/24
Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer'sPRNewsWire • 12/06/23
Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of TechnologyPRNewsWire • 11/02/23
Synaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's DiseasePRNewsWire • 09/26/23
Bryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent StudyPRNewsWire • 09/07/23
Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple SclerosisPRNewsWire • 07/19/23
Synaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World Congress of NeurosciencePRNewsWire • 07/13/23
Synaptogenix Provides Corporate Update and Outlines Potential Business OpportunitiesPRNewsWire • 03/07/23
Synaptogenix Announces Topline Results from NIH-Sponsored Phase 2 Clinical Trial of Bryostatin-1 for Advanced Alzheimer's DiseasePRNewsWire • 12/16/22
Synaptogenix Announces Live Appearance of its President and CSO on Streaming Financial News NetworkPRNewsWire • 08/12/22